CN115957311A - Application of histone methyltransferase EZH2 in medicine for promoting optic nerve remyelination - Google Patents
Application of histone methyltransferase EZH2 in medicine for promoting optic nerve remyelination Download PDFInfo
- Publication number
- CN115957311A CN115957311A CN202310021679.1A CN202310021679A CN115957311A CN 115957311 A CN115957311 A CN 115957311A CN 202310021679 A CN202310021679 A CN 202310021679A CN 115957311 A CN115957311 A CN 115957311A
- Authority
- CN
- China
- Prior art keywords
- ezh2
- optic nerve
- remyelination
- aav
- promoting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001328 optic nerve Anatomy 0.000 title claims abstract description 42
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 230000001737 promoting effect Effects 0.000 title claims abstract description 12
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 title abstract description 15
- 208000016192 Demyelinating disease Diseases 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 101150090105 Ezh2 gene Proteins 0.000 claims abstract description 11
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims abstract description 10
- 229960005127 montelukast Drugs 0.000 claims abstract description 10
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 claims abstract description 10
- 102000006386 Myelin Proteins Human genes 0.000 claims description 11
- 108010083674 Myelin Proteins Proteins 0.000 claims description 11
- 210000005012 myelin Anatomy 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 6
- 230000004069 differentiation Effects 0.000 claims description 5
- 230000008439 repair process Effects 0.000 claims description 5
- 230000035800 maturation Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000002025 microglial effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 abstract description 20
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 abstract description 12
- 230000023105 myelination Effects 0.000 abstract description 8
- 206010012305 Demyelination Diseases 0.000 abstract description 7
- 208000030768 Optic nerve injury Diseases 0.000 abstract description 7
- 238000011284 combination treatment Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 238000011813 knockout mouse model Methods 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 9
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000003125 immunofluorescent labeling Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003007 myelin sheath Anatomy 0.000 description 4
- 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- 102100036817 Ankyrin-3 Human genes 0.000 description 3
- 101710191051 Ankyrin-3 Proteins 0.000 description 3
- 102100040501 Contactin-associated protein 1 Human genes 0.000 description 3
- 101710196304 Contactin-associated protein 1 Proteins 0.000 description 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000003959 neuroinflammation Effects 0.000 description 3
- 208000008795 neuromyelitis optica Diseases 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 108010036115 Histone Methyltransferases Proteins 0.000 description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 210000003666 myelinated nerve fiber Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 108010000597 Polycomb Repressive Complex 2 Proteins 0.000 description 1
- 102000002272 Polycomb Repressive Complex 2 Human genes 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000028315 developmental maturation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an application of histone methyltransferase EZH2 in a medicine for promoting optic nerve remyelination, and relates to the technical field of biomedicine. The invention discloses the effect of EZH2 in the process of optic nerve myelination; through an Ezh2 gene conditional knockout mouse optic nerve injury model, AAV-EZH2, AAV-CNTF, montelukast and PLX3397 are combined to treat optic nerve pinches, and the result proves that EZH2 can be used as a new molecular target for central nervous system demyelination diseases. The EZH2 combination treatment scheme is used for promoting optic nerve remyelination and provides a new strategy for remyelination treatment after central nervous system demyelination.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to a composition and application thereof in a medicine for promoting optic nerve remyelination.
Background
In recent years, the incidence of Central Nervous System (CNS) demyelinating diseases has been increasing year by year, and the disease is mainly a Multiple Sclerosis (MS) and inflammatory demyelination, and the common diseases mainly include Multiple Sclerosis (NMO) and Neuromyelitis Optica (NMO).
The main affected part of the CNS demyelinating disease is myelin, which is a biofilm and wraps axons, and has the functions of insulating and accelerating electric pulse conduction, ensuring neuronal metabolic supply and the like. Oligodendrocytes (OLs) are involved in axonal myelination in the CNS, ensuring saltatory neurotransmission. Myelin plays a crucial role in the developmental maturation of the CNS and plasticity of neural tissue. Failure of remyelination following either a myelination defect or injury can lead to various neurodevelopmental disorders, intellectual impairment, and autism spectrum disorders. At the same time, defects in myelin repair are also the basis for neurodegenerative diseases such as multiple sclerosis and leukodystrophy. The degree of myelin destruction and regeneration is closely related to the severity of the disease and the effectiveness of the treatment. At the present time, it is known that,
the treatment of CNS demyelinating diseases is one of the difficulties in the neuro-medical field, and better methods for treating and improving prognosis can be found by further deeply researching the pathology, physiology and pathogenesis of the CNS demyelinating diseases. The optic nerve, an important component of the CNS, has been the subject of significant investigation for CNS injury repair. Both optic neuritis and optic nerve injury produce typical demyelinating lesions clinically. Optic neuritis is an acute inflammation of the optic nerve characterized by sudden loss of central vision and eye movement pain. Often associated with MS, patients can fully restore vision, usually by treatment, but may also develop irreversible vision loss. Currently, clinical treatment is mainly focused on relieving neuroinflammation and reducing the incidence of demyelination, but does not cure radically.
Disclosure of Invention
The invention aims to solve the technical problem that clinical treatment in the prior art mainly focuses on relieving neuroinflammation and reducing the incidence rate of demyelination, but cannot radically cure the neuroinflammation and the demyelination.
In order to achieve the purpose, the invention adopts the following technical scheme:
use of EZH2 for the manufacture of a medicament for promoting myelin repair or for the treatment of CNS demyelinating diseases.
The application also provides a medicine for treating CNS demyelinating diseases, which comprises AAV-EZH2 and AAV-CNTF.
Preferably, when the medicament is used for early promotion of initial differentiation of OPCs, the medicament further comprises Montelukast.
Preferably, when the medicament is used for delaying the clearance of microglia and promoting the maturation of OLs, the medicament further comprises PLX3397.
The application confirms the function of the Ezh2 gene in the formation of optic nerve myelin sheath, and confirms the influence of the Ezh2 gene on the differentiation of oligodendrocyte precursor cells, myelination and other related functions; through an Ezh2 gene conditional knockout mouse optic nerve injury model, an oligodendrocyte cell and neuron co-culture model, the effect of the Ezh2 gene on the formation and maintenance process of central nervous system myelin sheaths and the influence of the Ezh2 gene on the functions of the oligodendrocyte proliferation, differentiation and myelination are clarified from the molecular level, the cell level, the tissue level and the overall level, and a new molecular target spot is provided for the demyelinating diseases of the central nervous system. The AAV-EZH2 combined treatment scheme is intended to promote optic nerve remyelination, and a new strategy is provided for remyelination treatment after central nervous system demyelination.
Drawings
FIG. 1 illustrates the principle of the EZH2 combination regimen of the present invention for promoting remyelination of optic nerves;
FIG. 2 shows 10 weeks old wild type and Ezh2 fl/fl Olig1-Cre mouse optic nerve anti-MBP (marker myelin sheath), GST pi (marker oligodendrocyte) and DAPI immunofluorescence staining results suggest Ezh2 fl/fl Olig1-Cre mice had optic nerve myelin development disturbance compared to control group;
FIG. 3 is a related drawing showing the following results in example 4 of the present invention, showing that the mouse was subjected to intravitreal injection of AAV-CNTF virus to prepare an optic nerve pinching model 14 days after the intravitreal injection of AAV-CNTF virus, that Montelukast and PLX3397 were continuously administered for 21 days after the optic nerve pinching to promote remyelination, that CTB555 neuroproberts were intravitreally injected for 19 days after the optic nerve pinching, that materials were taken 21 days after the optic nerve pinching, and that Langfield's knot immunofluorescent staining (Caspr, ankyrin-G) and TEM results suggest Ezh2 fl/fl Olig1-Cre mice had significantly reduced remyelination of optic nerves compared to the control group.
FIG. 4 is a related drawing in example 4 of the present invention, which is used to show that 14 days after the injection of AAV-CNTF or AAV-Control virus into the vitreous of mice and the preparation of optic nerve clamp wound model after the injection of AAV-EZH2 into the optic nerve, the combination treatment of Montelukast and PLX3397 was continuously administered 21 days after the optic nerve clamp wound to promote the regeneration of myelin sheath, the material was taken 21 days after the optic nerve clamp wound, and the statistics of transmission electron microscopy suggest that the proportion of optic nerve myelinated nerve fibers in the EZH2 combination treatment group is significantly increased compared with the Control group.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to specific embodiments.
Referring to FIG. 1, the present application provides the use of enhancer of Zeste Gene homolog 2 (Enhancerorf homogeneity 2, EZH2) in the preparation of a medicament for promoting myelin repair or for treating CNS demyelinating diseases.
Wherein, EZH2 is one of the core subunits of polycomb repressive complex 2 (PRC 2), has histone methyltransferase activity, and is responsible for catalyzing the trimethylation of lysine at 27 th position of histone H3 (H3K 27me 3).
The application also provides a medicine for treating CNS demyelinating diseases, which comprises AAV-EZH2 and AAV-CNTF.
When the drug is used to promote the initial differentiation of Oligodendrocyte Precursor Cells (OPCs) at an early stage, the drug further includes Montelukast.
When the drug is used for delaying the clearance of microglia and promoting the maturation of Oligodendrocytes (OLs), the drug further comprises PLX3397.
The present application is illustrated below with reference to specific examples:
example 1:
effect of EZH2 on optic nerve myelination:
specifically, a conditional knockout mouse (Ezh 2) specifically knocking out the Ezh2 gene in Oligodendrocytes (OLs) of the central nervous system (Ezh 2) has been obtained in this example, referring to FIG. 2, by specifically knocking out the Ezh2 gene (Ezh 2fl/fl; olig1-Cre mouse, abbreviated as Ezh2 cKO; see FIG. 2 for short) fl/fl Olig1-Cre, hereinafter referred to as Ezh2 cKO), found that the expression of myelin associated protein MBP in the optic nerve of the Ezh2 cKO mice was significantly reduced and the number of mature oligodendrocytes (GST pi-positive) was significantly reduced, compared to the wild-type mice. From the above results it follows: mutations in the Ezh2 gene in Oligodendrocytes (OLs) may result in the loss of cells of the mature OLs lineage, which in turn causes impairment of optic nerve myelin development.
Example 2:
loss of EZH2 function in optic nerve OLs leads to optic nerve remyelination disorders. The axogenesis-promoting treatment regimen AAV-CNTF was given 14 days before the pinch, and the Montelukast and PLX3397 combination treatment regimen was given daily within 21 days after the pinch. Ezh2 was suggested by immunofluorescent staining of Langfei junctions (Caspr, ankyrin-G) and transmission electron microscopy results fl/fl Olig1-Cre mice had significantly reduced remyelination of optic nerves compared to the control group.
Referring to FIG. 3, an optic nerve injury model was prepared 14 days after intravitreal injection of AAV-CNTF virus in mice, montelukast and PLX3397 were administered continuously for 21 days after optic nerve injury to promote remyelination, CTB555 neurotracer was injected intravitreally 19 days after optic nerve injury, materials were taken 21 days after optic nerve injury, and Langerhans' knot immunofluorescent staining (Caspr, ankyrin-G)) And the result of the transmission electron microscope suggests Ezh2 fl/fl Olig1-Cre mice had significantly reduced remyelination of optic nerves compared to the control group.
Example 3:
the effect of the AAV-EZH2 combination remyelination therapy on remyelination after optic nerve pinch is to promote remyelination after optic nerve pinch. The axotrophic regeneration treatment protocol AAV-CNTF and myelinating AAV-EZH2 were administered 14 days before the pinch, and the Montelukast and PLX3397 combination treatment protocol was administered daily for 21 days after the pinch. The adult mouse optic nerve overexpresses the Ezh2 gene in OLs by injecting adeno-associated virus, and the effect of the AAV-EZH2 combination treatment regimen on remyelination after optic nerve bruise is clarified by transmission electron microscopy.
Referring to fig. 4, an optic nerve pinch model was prepared 14 days after intravitreal injection of AAV-CNTF or AAV-Control virus and AAV-EZH2 in optic nerve in wild type mice, montelukast and PLX3397 were continuously administered for 21 days after the optic nerve pinch to promote myelination, materials were taken 21 days after the optic nerve pinch, and the transmission electron microscopy statistics suggested that the ratio of optic nerve myelinated nerve fibers in the EZH2 combination treatment group was significantly increased compared to each Control group.
Based on the above examples, EZH2, as a histone methyltransferase, affects myelin-associated protein expression and plays an important role in myelination, maintenance and remyelination of the central nervous system optic nerve.
Claims (4)
- Use of ezh2 for the preparation of a medicament for promoting optic nerve myelin repair or for the treatment of CNS demyelinating diseases.
- 2. A medicament for treating CNS demyelinating diseases, comprising: including AAV-EZH2 and AAV-CNTF.
- 3. A medicament for the treatment of CNS demyelinating diseases according to claim 2, characterized in that: when the drug is used to promote the initial differentiation of OPCs early, the drug also includes Montelukast.
- 4. A medicament for the treatment of CNS demyelinating diseases according to claim 2, wherein: when the medicament is used for delaying microglial clearance and promoting maturation of OLs, the medicament also comprises PLX3397.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310021679.1A CN115957311A (en) | 2023-01-06 | 2023-01-06 | Application of histone methyltransferase EZH2 in medicine for promoting optic nerve remyelination |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310021679.1A CN115957311A (en) | 2023-01-06 | 2023-01-06 | Application of histone methyltransferase EZH2 in medicine for promoting optic nerve remyelination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115957311A true CN115957311A (en) | 2023-04-14 |
Family
ID=87353018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310021679.1A Pending CN115957311A (en) | 2023-01-06 | 2023-01-06 | Application of histone methyltransferase EZH2 in medicine for promoting optic nerve remyelination |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115957311A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111705069A (en) * | 2020-06-19 | 2020-09-25 | 武汉纽福斯生物科技有限公司 | Multi-neurotrophic factor combined expression vector and application thereof |
| CN111840285A (en) * | 2020-06-10 | 2020-10-30 | 苏州安康盟医疗科技有限公司 | GPR17 and/or CSFR1 receptor inhibitors |
| WO2020263484A1 (en) * | 2019-06-28 | 2020-12-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuromyelitis optica spectrum diseases |
| WO2021222507A1 (en) * | 2020-05-01 | 2021-11-04 | The Children's Medical Center Corporation | Compositions and methods of promoting myelination |
| US20220160897A1 (en) * | 2020-11-25 | 2022-05-26 | The Hong Kong University Of Science And Technology | Method for Stimulating Axonal Regeneration |
-
2023
- 2023-01-06 CN CN202310021679.1A patent/CN115957311A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020263484A1 (en) * | 2019-06-28 | 2020-12-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuromyelitis optica spectrum diseases |
| WO2021222507A1 (en) * | 2020-05-01 | 2021-11-04 | The Children's Medical Center Corporation | Compositions and methods of promoting myelination |
| CN111840285A (en) * | 2020-06-10 | 2020-10-30 | 苏州安康盟医疗科技有限公司 | GPR17 and/or CSFR1 receptor inhibitors |
| CN111705069A (en) * | 2020-06-19 | 2020-09-25 | 武汉纽福斯生物科技有限公司 | Multi-neurotrophic factor combined expression vector and application thereof |
| US20220160897A1 (en) * | 2020-11-25 | 2022-05-26 | The Hong Kong University Of Science And Technology | Method for Stimulating Axonal Regeneration |
Non-Patent Citations (4)
| Title |
|---|
| FATEMEH TAHMASEBI ET AL.: "Effect of CSF1R inhibitor on glial cells population and remyelination in the cuprizone model", NEUROPEPTIDES, 31 October 2021 (2021-10-31), pages 1 - 11 * |
| XUE-WEI WANG ET AL.: "Histone methyltransferase Ezh2 coordinates mammalian axon regeneration via epigenetic regulation of key regenerative pathways", BIORXIV, 19 April 2022 (2022-04-19), pages 8 - 2 * |
| YUN XIAO ET AL.: "A targeted extracellular vesicles loaded with montelukast in the treatment of demyelinating diseases", BIOCHEMBIOPHYS RES COMMUN, vol. 594, 26 February 2022 (2022-02-26), pages 31 - 37, XP086947573, DOI: 10.1016/j.bbrc.2022.01.051 * |
| 赵忠惠 等: "睫状神经营养因子对大鼠脑缺血后髓鞘再生的影响", 神经解剖学杂志, vol. 35, no. 1, 31 January 2019 (2019-01-31), pages 47 - 51 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miron et al. | Cells of the oligodendroglial lineage, myelination, and remyelination | |
| Fischer et al. | Reactive retinal microglia, neuronal survival, and the formation of retinal folds and detachments | |
| Levine et al. | Activation and proliferation of endogenous oligodendrocyte precursor cells during ethidium bromide-induced demyelination | |
| AU783448B2 (en) | Induced regeneration and repair of damaged neurons and nerve axon myelin | |
| Ramekers et al. | Neurotrophins and their role in the cochlea | |
| US20230277623A1 (en) | Composition for Controlling Neuronal Outgrowth | |
| Lindsay et al. | Human olfactory mesenchymal stromal cell transplants promote remyelination and earlier improvement in gait co‐ordination after spinal cord injury | |
| CN116077626A (en) | Treatment of neurological disorders using a combination of RXR agonists and thyroid hormones | |
| Chari et al. | New insights into remyelination failure in multiple sclerosis: implications for glial cell transplantation | |
| Zhang et al. | Mechanism and prevention of spiral ganglion neuron degeneration in the cochlea | |
| JP2002544233A (en) | Glycosaminoglycans having an average molecular weight equal to 2,400 D suitable for the treatment of senile dementia | |
| CN115957311A (en) | Application of histone methyltransferase EZH2 in medicine for promoting optic nerve remyelination | |
| Li et al. | Scorpion venom heat‐resistant synthesized peptide ameliorates 6‐OHDA‐induced neurotoxicity and neuroinflammation: likely role of Nav1. 6 inhibition in microglia | |
| Shao et al. | Promotion of axon regeneration and inhibition of astrocyte activation by alpha A-crystallin on crushed optic nerve | |
| Quan et al. | Hydralazine plays an immunomodulation role of pro-regeneration in a mouse model of spinal cord injury | |
| Herrero et al. | Gangliosides and parkinsonism | |
| US20190314300A1 (en) | Compounds and methods of promoting myelination | |
| Piekarz et al. | Pharmacologic treatment with OKN-007 reduces alpha-motor neuron loss in spinal cord of aging mice | |
| CN115843750A (en) | Method for constructing optic nerve myelination defect mouse model | |
| French et al. | Alexander's disease presenting as astrocytoma. | |
| Tan et al. | Influence of adjuvant levetiracetam therapy on serum nerve cytokines and apoptosis molecules in patients with refractory partial epileptic seizure | |
| US11963969B2 (en) | Method for prevention or treatment of amyotrophic lateral sclerosis by administering gastrodin | |
| Kuramoto et al. | Injection of muscimol, a GABAa agonist into the anterior thalamic nucleus, suppresses hippocampal neurogenesis in amygdala-kindled rats | |
| Msheik | Central and peripheral neuroinflammation: A focus on the macrophage | |
| Xue et al. | Alleviating early demyelination in ischaemia/reperfusion by inhibiting sphingosine‐1‐phosphate receptor 2 could protect visual function from impairment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |